Lercanidipine is a calcium channel blocker for the management of hypertension. It is sold under various commercial names including Zanidip.
- Mechanism
- Curator reviewed
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
- Primary indication
- For the treatment of Hypertension, management of angina pectoris and Raynaud's syndromeCurator reviewed · 3 structured indications
- Formula / weight
- C36H41N3O6 · 611.7272 g/mol (avg)
Resolves to
ZDXUKAKRHYTAKV-UHFFFAOYSA-NSMILESCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1What you can answer from here — as of September 16, 2026
Which drugs share a target with Lercanidipine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account